Abstract
Background: Pridopidine, a compound in clinical trials for Huntington's disease treatment, was originally synthesized as a dopamine D2 receptor (D2R) ligand, but later found to possess higher affinity for the sigma-1 receptor (S1R). However, the putative contributions of D2R and S1R to the behavioral profile of acutely administered pridopidine have not been investigated.
Objective: The present study sought to compare the effects of acute pridopidine on wild-type vs. D2R and S1R knockout mice, at high (60 mg/kg) and low (6 mg/kg) doses.
Method: Pridopidine effects on basal and phencyclidine-induced locomotor activity was measured in the open field test. Additionally, the actions of pridopidine on prepulse inhibition was measured in animals treated with saline or phencyclidine.
Results: Whereas inhibition of spontaneous and phencyclidine-induced locomotion was readily observed at 60 mg/kg pridopidine, neither locomotor stimulation in habituated mice, nor any effects on prepulse inhibition were detected upon pridopidine treatment. Surprisingly, inhibition of spontaneous locomotion was unaffected by both D2R and S1R deletion.
Conclusion: The present results suggest the involvement of additional targets, besides D2R and S1R, in mediating locomotor inhibition by pridopidine.
Keywords: Sigma-1 receptor, dopamine receptor, knockout mice, phencyclidine, open field, prepulse inhibition.
CNS & Neurological Disorders - Drug Targets
Title:Effects of the Dopamine Stabilizer, Pridopidine, on Basal and Phencyclidine-Induced Locomotion: Role of Dopamine D2 and Sigma-1 Receptors
Volume: 17 Issue: 7
Author(s): Kristoffer Sahlholm*, Marta Valle-Leon, Jaume Taura, Victor Fernandez-Duenas and Francisco Ciruela*
Affiliation:
- Unitat de Farmacologia, Departament Patologia i Terapeutica Experimental, Facultat de Medicina i Ciencies de la Salut, IDIBELL-Universitat de Barcelona, L`Hospitalet de Llobregat, Barcelona,Spain
- Unitat de Farmacologia, Departament Patologia i Terapeutica Experimental, Facultat de Medicina i Ciencies de la Salut, IDIBELL-Universitat de Barcelona, L`Hospitalet de Llobregat, Barcelona,Spain
Keywords: Sigma-1 receptor, dopamine receptor, knockout mice, phencyclidine, open field, prepulse inhibition.
Abstract: Background: Pridopidine, a compound in clinical trials for Huntington's disease treatment, was originally synthesized as a dopamine D2 receptor (D2R) ligand, but later found to possess higher affinity for the sigma-1 receptor (S1R). However, the putative contributions of D2R and S1R to the behavioral profile of acutely administered pridopidine have not been investigated.
Objective: The present study sought to compare the effects of acute pridopidine on wild-type vs. D2R and S1R knockout mice, at high (60 mg/kg) and low (6 mg/kg) doses.
Method: Pridopidine effects on basal and phencyclidine-induced locomotor activity was measured in the open field test. Additionally, the actions of pridopidine on prepulse inhibition was measured in animals treated with saline or phencyclidine.
Results: Whereas inhibition of spontaneous and phencyclidine-induced locomotion was readily observed at 60 mg/kg pridopidine, neither locomotor stimulation in habituated mice, nor any effects on prepulse inhibition were detected upon pridopidine treatment. Surprisingly, inhibition of spontaneous locomotion was unaffected by both D2R and S1R deletion.
Conclusion: The present results suggest the involvement of additional targets, besides D2R and S1R, in mediating locomotor inhibition by pridopidine.
Export Options
About this article
Cite this article as:
Sahlholm Kristoffer *, Valle-Leon Marta , Taura Jaume , Fernandez-Duenas Victor and Ciruela Francisco *, Effects of the Dopamine Stabilizer, Pridopidine, on Basal and Phencyclidine-Induced Locomotion: Role of Dopamine D2 and Sigma-1 Receptors, CNS & Neurological Disorders - Drug Targets 2018; 17 (7) . https://dx.doi.org/10.2174/1871527317666180627103337
DOI https://dx.doi.org/10.2174/1871527317666180627103337 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Hold Onto Your Hat! - Handling the Roller Coaster Emotions of the College Application Process
Adolescent Psychiatry Hematologic Abnormalities in the Antiphospholipid Syndrome
Current Rheumatology Reviews Understanding the Molecular Properties and Metabolism of Top Prescribed Drugs
Current Topics in Medicinal Chemistry Early-phase 18F-AV-45 PET Imaging can Detect Crossed Cerebellar Diaschisis Following Carotid Artery Stenosis and Cerebral Hypoperfusion
Current Neurovascular Research Recent Clinical Aspects of Eating Disorders
Reviews on Recent Clinical Trials Molecular Modelling and QSAR of Reversible Acetylcholines-terase Inhibitors
Current Medicinal Chemistry Cholinergic System Dysfunction and Neurodegenerative Diseases: Cause or Effect?
CNS & Neurological Disorders - Drug Targets Recent Advances in Asthma Genetics and Antiasthma Therapy
Current Respiratory Medicine Reviews Imidazoles as Promising Scaffolds for Antibacterial Activity: A Review
Mini-Reviews in Medicinal Chemistry Tumor Necrosis Factor Blockade for Treatment of Inflammatory Bowel Disease: Efficacy and Safety
Current Molecular Pharmacology Adolescent HIV-1 Transgenic Rats: Evidence for Dopaminergic Alterations in Behavior and Neurochemistry Revealed by Methamphetamine Challenge
Current HIV Research Voltage-Gated Calcium Channels as Targets for the Treatment of Chronic Pain
Current Drug Targets - CNS & Neurological Disorders HIV Infection and Myocardial Infarction
Current HIV Research Impact of Short-Term Educational and Behavioral Therapy on Childhood Obesity
Vascular Disease Prevention (Discontinued) Multi-Target Directed Compounds with Antioxidant and/or Anti- Inflammatory Properties as Potent Agents for Alzheimer’s Disease
Medicinal Chemistry Endogenous Agmatine Inhibits Cerebral Vascular Matrix Metalloproteinases Expression by Regulating Activating Transcription Factor 3 and Endothelial Nitric Oxide Synthesis
Current Neurovascular Research L-Type Voltage-Dependent Calcium Channels As Therapeutic Targets for Neurodegenerative Diseases
Current Medicinal Chemistry Small Molecules Targeting the NMDA Receptor Complex as Drugs for Neuropathic Pain
Mini-Reviews in Medicinal Chemistry Drug Delivery Technologies and Stem Cells for Tissue Repair and Regeneration
Current Pharmaceutical Biotechnology Multitarget Opioid/Non-opioid Ligands: A Potential Approach in Pain Management
Current Medicinal Chemistry